Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies
The therapeutic landscape for lymphomas is quite diverse and includes active surveillance, chemotherapy, immunotherapy, radiation therapy, and even stem cell transplant. Advances in the field have led to the development of targeted therapies, agents that specifically act against a specific component...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.948513/full |
| _version_ | 1818065369871417344 |
|---|---|
| author | Anagha Deshpande Javier Munoz |
| author_facet | Anagha Deshpande Javier Munoz |
| author_sort | Anagha Deshpande |
| collection | DOAJ |
| description | The therapeutic landscape for lymphomas is quite diverse and includes active surveillance, chemotherapy, immunotherapy, radiation therapy, and even stem cell transplant. Advances in the field have led to the development of targeted therapies, agents that specifically act against a specific component within the critical molecular pathway involved in tumorigenesis. There are currently numerous targeted therapies that are currently Food and Drug Administration (FDA) approved to treat certain lymphoproliferative disorders. Of many, some of the targeted agents include rituximab, brentuximab vedotin, polatuzumab vedotin, nivolumab, pembrolizumab, mogamulizumab, vemurafenib, crizotinib, ibrutinib, cerdulatinib, idelalisib, copanlisib, venetoclax, tazemetostat, and chimeric antigen receptor (CAR) T-cells. Although these agents have shown strong efficacy in treating lymphoproliferative disorders, the complex biology of the tumors have allowed for the malignant cells to develop various mechanisms of resistance to the targeted therapies. Some of the mechanisms of resistance include downregulation of the target, antigen escape, increased PD-L1 expression and T-cell exhaustion, mutations altering the signaling pathway, and agent binding site mutations. In this manuscript, we discuss and highlight the mechanism of action of the above listed agents as well as the different mechanisms of resistance to these agents as seen in lymphoproliferative disorders. |
| first_indexed | 2024-12-10T14:50:48Z |
| format | Article |
| id | doaj.art-b3d8e0f826a34d4bb5288f5e5b321eb8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T14:50:48Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b3d8e0f826a34d4bb5288f5e5b321eb82022-12-22T01:44:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.948513948513Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategiesAnagha Deshpande0Javier Munoz1Mayo Clinic Alix School of Medicine, Scottsdale, AZ, United StatesDivision of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, United StatesThe therapeutic landscape for lymphomas is quite diverse and includes active surveillance, chemotherapy, immunotherapy, radiation therapy, and even stem cell transplant. Advances in the field have led to the development of targeted therapies, agents that specifically act against a specific component within the critical molecular pathway involved in tumorigenesis. There are currently numerous targeted therapies that are currently Food and Drug Administration (FDA) approved to treat certain lymphoproliferative disorders. Of many, some of the targeted agents include rituximab, brentuximab vedotin, polatuzumab vedotin, nivolumab, pembrolizumab, mogamulizumab, vemurafenib, crizotinib, ibrutinib, cerdulatinib, idelalisib, copanlisib, venetoclax, tazemetostat, and chimeric antigen receptor (CAR) T-cells. Although these agents have shown strong efficacy in treating lymphoproliferative disorders, the complex biology of the tumors have allowed for the malignant cells to develop various mechanisms of resistance to the targeted therapies. Some of the mechanisms of resistance include downregulation of the target, antigen escape, increased PD-L1 expression and T-cell exhaustion, mutations altering the signaling pathway, and agent binding site mutations. In this manuscript, we discuss and highlight the mechanism of action of the above listed agents as well as the different mechanisms of resistance to these agents as seen in lymphoproliferative disorders.https://www.frontiersin.org/articles/10.3389/fonc.2022.948513/fulllymphomatargeted therapyresistancemechanism of actionCAR T-cellstazemetostat |
| spellingShingle | Anagha Deshpande Javier Munoz Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies Frontiers in Oncology lymphoma targeted therapy resistance mechanism of action CAR T-cells tazemetostat |
| title | Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies |
| title_full | Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies |
| title_fullStr | Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies |
| title_full_unstemmed | Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies |
| title_short | Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies |
| title_sort | targeted and cellular therapies in lymphoma mechanisms of escape and innovative strategies |
| topic | lymphoma targeted therapy resistance mechanism of action CAR T-cells tazemetostat |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.948513/full |
| work_keys_str_mv | AT anaghadeshpande targetedandcellulartherapiesinlymphomamechanismsofescapeandinnovativestrategies AT javiermunoz targetedandcellulartherapiesinlymphomamechanismsofescapeandinnovativestrategies |